4.6 Article

Hybrids of Imatinib with Quinoline: Synthesis, Antimyeloproliferative Activity Evaluation, and Molecular Docking

期刊

PHARMACEUTICALS
卷 15, 期 3, 页码 -

出版社

MDPI
DOI: 10.3390/ph15030309

关键词

cancer; imatinib; PAPP; quinoline; 1,2,3-triazole; tyrosine kinase inhibitors

资金

  1. Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro-FAPERJ [CNE-FAPERJ E-26/202.805/2017, E-26/200.861/2021]
  2. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brazil (CAPES) [001]

向作者/读者索取更多资源

Imatinib is a BCR-ABL inhibitor, but its resistance and toxicity highlight the need for new inhibitors. This study synthesized imatinib derivatives containing quinoline moieties and evaluated their activity against leukemia cells. Compound 2g showed promising activity and could be a potential treatment for chronic myeloid leukemia (CML) patients with acquired resistance to imatinib.
Imatinib (IMT) is the first-in-class BCR-ABL commercial tyrosine kinase inhibitor (TKI). However, the resistance and toxicity associated with the use of IMT highlight the importance of the search for new TKIs. In this context, heterocyclic systems, such as quinoline, which is present as a pharmacophore in the structure of the TKI inhibitor bosutinib (BST), have been widely applied. Thus, this work aimed to obtain new hybrids of imatinib containing quinoline moieties and evaluate them against K562 cells. The compounds were synthesized with a high purity degree. Among the produced molecules, the inhibitor 4-methyl-N3-(4-(pyridin-3-yl)pyrimidin-2-yl)-N1-(quinolin-4-yl)benzene1,3-diamine (2g) showed a suitable reduction in cell viability, with a CC50 value of 0.9 mu M (IMT, CC50 = 0.08 mu M). Molecular docking results suggest that the interaction between the most active inhibitor 2g and the BCR-ABL1 enzyme occurs at the bosutinib binding site through a competitive inhibition mechanism. Despite being less potent and selective than IMT, 2g is a suitable prototype for use in the search for new drugs against chronic myeloid leukemia (CML), especially in patients with acquired resistance to IMT.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据